Takeda's candesartan successor, azilsartan, moves forward in hypertension
This article was originally published in Scrip
There has been some positive news for Takeda's late-stage pipeline with the start of Phase III hypertension trials in Japan for the company's candesartan successor, azilsartan (TAK-536).
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Japanese firm exercises option after promising Phase I results in disorder with no approved drugs, in deal that builds out its celiac pipeline.
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.